вторник, 18 сентября 2012 г.

Novartis drug Ilaris wins FDA approval - Triangle Business Journal:

ycoguqi.wordpress.com
Ilaris will be used to trea cryopyrin-associated periodic syndrome, or CAPS, a diseasde caused by a singl e gene mutation that leads to overproductionb of a protein thatencourages inflammation. Symptoms include rash, fever, headaches, joint pain and conjunctivitis. The disease can lead to bone and joint deformities and central nervoussystej damage. Long term, CAPS can be The Swiss pharmaceutical company, which is buildin a $600 million flu vaccine plant inHolluy Springs, says Illaris acts by selectively blocking the proteim causing the inflammation. Dr.
Hal a professor of pediatrics and medicine atthe , said in a statement that previous CAPS treatmentds have worked by suppressing the entirwe immune system. Newer treatments requires frequent injections. Ilaris needs to be administered only once everyeight weeks. Novartis (NYSE: NVS), is also studying Illariss in clinical trials for the treatmen t of systemic juvenile idiopathicarthritis (SJIA), as well as for chronic obstructive pulmonary disorder and type 2 diabetes. Novartizs has been granted orphan drug designation for SJIA in the United European Unionand Switzerland. The FDA grants orphan drug status for medicines treating diseases affecting fewerthan 200,00o0 people.
The designation allows a drug company tax incentives for clinical trialsx and marketing exclusivity for seven years if the drug is Constructionon Novartis’ Holly Springs plant is expectedc to be finished late this year or sometim next year. The facility eventually could employ up to300

Комментариев нет:

Отправить комментарий